Skip to main content
OpenTrials
Completed

NCT Number: NCT02430623

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urinary Bladder Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urinary Bladder Diseases Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Biological treatment center in Fuda cancer hospital

Guangzhou, Guangdong, 510000, China

About this study

By enrolling patients with unresectable Urinary Bladder Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Urinary Bladder Neoplasms.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Head and Urinary Bladder diagnosed by positive biopsy or non-invasive criteria,
  • Not suitable for surgical resection,
  • Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  • A prothrombin time ratio > 50%,
  • Platelet count > 80x10^9/L,
  • Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  • Able to comprehend and willing to sign the written informed consent form (ICF),
  • Have a life expectancy of at least 3 months.

Exclusion criteria

  • Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  • Any active implanted device (eg Pacemaker),
  • Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  • Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  • Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Treatment and study plan

Irreversible electroporation (IRE)

Procedure

Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.

Other names: NanoKnife

NanoKnife

Device

Primary outcomes

  1. Number of participants with Adverse events

    Time frame: 6 month

Secondary outcomes

  1. Percentage of lesions that show no sign of recurrence 12 months after IRE

    Time frame: 12 months

  2. A minimum and maximum range of voltage for safe and effective IRE

    Time frame: 3 months

  3. Progress free disease (PFS)

    Time frame: 12 months

  4. Overall survival (OS)

    Time frame: 36 months

    Patients will be followed for 36 months after IRE for OS analyzed.

Sponsors and collaborators

Lead sponsor

Fuda Cancer Hospital, Guangzhou

Other

Registry information

Official study title

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms: Phase I and Phase II Clinical Trial

Acronym: IRE

Important dates

Study start
2015
Primary completion
2020
Study completion
2021
First posted
Apr 30, 2015
Registry last updated
Sep 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.